Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of rocatinlimab in prurigo nodularis
ChiCTR2400094008Phase 3Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rocatinlimab in prurigo nodularis (PN) (3 arms), sponsored by Peking University First Hospital. Primary endpoints: Achieving at least a 4-point reduction from baseline in weekly average of daily Worst Itch Numeric Rating Scale score and WI-NRS score. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
rocatinlimab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on ChiCTR2400094008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094008.